{"success":true,"data":{"pressRelease":{"id":"53609","rtpr_id":"nACSqdXHja","ticker":"AIMD","exchange":"NASDAQ","all_tickers":["AIMD","AIMDW"],"title":"Zacks SCR Discusses Ainos' Expansion of Smell AI into Healthcare Infrastructure Through NTUH Study","author":"ACCESSWIRE","published_at":"2026-06-03T12:00:02.193Z","article_body":"HOUSTON, TX / ACCESS Newswire (https://www.accessnewswire.com/) / June 3, 2026\n/ Ainos, Inc. (NASDAQ:AIMD, AIMDW) (\"Ainos\" or the \"Company\"), a Smell AI\ncompany digitizing scent into machine-readable data for artificial\nintelligence applications, today announced that Zacks Small-Cap Research\n(\"Zacks SCR\") has published a new article discussing Ainos' recently announced\nhealthcare infrastructure study at National Taiwan University Hospital\n(\"NTUH\").\n\nThe article reviews Ainos' initiative to deploy AI Nose in a live emergency\ndepartment environment and explores the potential role of Smell AI in\nenvironmental monitoring, healthcare infrastructure, and artificial\nintelligence applications.\n\nAccording to the article, the Smell AI study represents an expansion of AI\nNose beyond semiconductor manufacturing environments and into healthcare\nsettings. The article also discusses Ainos' broader strategy of converting\nscent and volatile organic compound (VOC) signals into machine-readable Smell\nID data that can be analyzed by AI systems.\n\nThe article notes that the NTUH program is expected to generate thousands of\nhours of environmental monitoring data and highlights Ainos' efforts to\ndevelop a scalable Smell AI platform through AI Nose, Smell ID, and its Smell\nLanguage Model.\n\nThe full Zacks SCR article can be accessed here:\nhttps://scr.zacks.com/news/news-details/2026/Ainos-Expands-Smell-AI-into-Healthcare-Infrastructure-Through-New-NTUH-Study/default.aspx\n\nAbout AI Nose\n\nAI Nose digitizes scent into Smell ID, an AI-driven form of scent\nintelligence. The full-stack electronic nose platform integrates\nhigh-precision MEMS sensor arrays with proprietary AI algorithms designed to\nsupport ppb-level scent detection sensitivity, subject to application\nconditions and deployment configurations. Smell ID converts analog scent\nsignals into structured, actionable data, while the proprietary Smell Language\nModel (SLM) is designed to learn, classify, and contextualize complex scent\npatterns over time.\n\nBuilt upon more than a decade of accumulated scent data and deep medtech\nexpertise, AI Nose is designed to support continuous monitoring, predictive\nanalysis, and real-time alerts across industrial and manufacturing\nenvironments. AI Nose is offered under a SmellTech-as-a-Service architecture,\nintended to support ongoing access to scent intelligence, analytics, and\nAI-driven insights through subscription-based deployment models.\n\nAbout Ainos, Inc.\n\nAinos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering\nsmelltech and immune therapeutics. Its AI Nose platform and smell language\nmodel (SLM) digitize scent into Smell ID, a machine-readable data format,\npowering intelligent sensing across robotics, smart factories, and healthcare.\nThe company also develops VELDONA(®), a low-dose oral interferon targeting\nrare, autoimmune, and infectious diseases. Ainos, a fusion of \"AI\" and \"Nose,\"\nis redefining machine perception for the sensory age. To learn more, visit\nhttps://www.ainos.com. Follow Ainos on X, formerly known as Twitter,\n(@AinosInc) and LinkedIn (https://pr.report/ajky) to stay up-to-date. Visit\nmedia room https://ainos.suite.accessnewswire.com.\n\nForward-Looking Statements\n\nCertain statements in this press release are forward-looking statements within\nthe meaning of Section 27A of the Securities Act of 1933, as amended, and\nSection 21E of the Securities Exchange Act of 1934, as amended. All statements\nother than statements of historical fact are forward-looking statements.\nForward-looking statements are based on management's current assumptions and\nexpectations of future events and trends, which affect or may affect the\nCompany's business, strategy, operations or financial performance, and actual\nresults and other events may differ materially from those expressed or implied\nin such statements due to numerous risks and uncertainties. Forward-looking\nstatements are inherently subject to risks and uncertainties, some of which\ncannot be predicted or quantified. There are a number of important factors\nthat could cause actual results, developments, business decisions or other\nevents to differ materially from those contemplated by the forward-looking\nstatements in this press release. These factors include, among other things,\nour expectation that we will incur net losses for the foreseeable future; our\nability to become profitable; our ability to raise additional capital to\ncontinue our product development; our ability to accurately predict our future\noperating results; our ability to advance our current or future product\ncandidates through clinical trials, obtain marketing approval and ultimately\ncommercialize any product candidates we develop; the ability to obtain and\nmaintain regulatory approval of our product candidates; delays in completing\nthe development and commercialization of our current and future product\ncandidates; developing and commercializing additional products, including\ndiagnostic testing devices; our ability to compete in the marketplace;\ncompliance with applicable laws, regulations and tariffs, and factors\ndescribed in the Risk Factors section of our public filings with the\nSecurities and Exchange Commission (SEC). Because forward-looking statements\nare inherently subject to risks and uncertainties, you should not rely on\nthese forward-looking statements as predictions of future events. These\nforward-looking statements speak only as of the date of this press release\nand, except to the extent required by applicable law, the Company undertakes\nno obligation to update or revise these statements, whether as a result of any\nnew information, future events and developments or otherwise.\n\nContact Information\nInvestor Relations\nir@ainos.com\n\nSOURCE: Ainos, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/zacks-scr-discusses-ainos-expansion-of-smell-ai-into-healthcare-i-1172938)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSqdXHja","title":"Zacks SCR Discusses Ainos' Expansion of Smell AI into Healthcare Infrastructure Through NTUH Study","author":"ACCESSWIRE","ticker":"AIMD","created":"2026-06-03T12:00:02.193Z","tickers":["AIMD","AIMDW"],"exchange":"NASDAQ","article_body":"HOUSTON, TX / ACCESS Newswire (https://www.accessnewswire.com/) / June 3, 2026\n/ Ainos, Inc. (NASDAQ:AIMD, AIMDW) (\"Ainos\" or the \"Company\"), a Smell AI\ncompany digitizing scent into machine-readable data for artificial\nintelligence applications, today announced that Zacks Small-Cap Research\n(\"Zacks SCR\") has published a new article discussing Ainos' recently announced\nhealthcare infrastructure study at National Taiwan University Hospital\n(\"NTUH\").\n\nThe article reviews Ainos' initiative to deploy AI Nose in a live emergency\ndepartment environment and explores the potential role of Smell AI in\nenvironmental monitoring, healthcare infrastructure, and artificial\nintelligence applications.\n\nAccording to the article, the Smell AI study represents an expansion of AI\nNose beyond semiconductor manufacturing environments and into healthcare\nsettings. The article also discusses Ainos' broader strategy of converting\nscent and volatile organic compound (VOC) signals into machine-readable Smell\nID data that can be analyzed by AI systems.\n\nThe article notes that the NTUH program is expected to generate thousands of\nhours of environmental monitoring data and highlights Ainos' efforts to\ndevelop a scalable Smell AI platform through AI Nose, Smell ID, and its Smell\nLanguage Model.\n\nThe full Zacks SCR article can be accessed here:\nhttps://scr.zacks.com/news/news-details/2026/Ainos-Expands-Smell-AI-into-Healthcare-Infrastructure-Through-New-NTUH-Study/default.aspx\n\nAbout AI Nose\n\nAI Nose digitizes scent into Smell ID, an AI-driven form of scent\nintelligence. The full-stack electronic nose platform integrates\nhigh-precision MEMS sensor arrays with proprietary AI algorithms designed to\nsupport ppb-level scent detection sensitivity, subject to application\nconditions and deployment configurations. Smell ID converts analog scent\nsignals into structured, actionable data, while the proprietary Smell Language\nModel (SLM) is designed to learn, classify, and contextualize complex scent\npatterns over time.\n\nBuilt upon more than a decade of accumulated scent data and deep medtech\nexpertise, AI Nose is designed to support continuous monitoring, predictive\nanalysis, and real-time alerts across industrial and manufacturing\nenvironments. AI Nose is offered under a SmellTech-as-a-Service architecture,\nintended to support ongoing access to scent intelligence, analytics, and\nAI-driven insights through subscription-based deployment models.\n\nAbout Ainos, Inc.\n\nAinos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering\nsmelltech and immune therapeutics. Its AI Nose platform and smell language\nmodel (SLM) digitize scent into Smell ID, a machine-readable data format,\npowering intelligent sensing across robotics, smart factories, and healthcare.\nThe company also develops VELDONA(®), a low-dose oral interferon targeting\nrare, autoimmune, and infectious diseases. Ainos, a fusion of \"AI\" and \"Nose,\"\nis redefining machine perception for the sensory age. To learn more, visit\nhttps://www.ainos.com. Follow Ainos on X, formerly known as Twitter,\n(@AinosInc) and LinkedIn (https://pr.report/ajky) to stay up-to-date. Visit\nmedia room https://ainos.suite.accessnewswire.com.\n\nForward-Looking Statements\n\nCertain statements in this press release are forward-looking statements within\nthe meaning of Section 27A of the Securities Act of 1933, as amended, and\nSection 21E of the Securities Exchange Act of 1934, as amended. All statements\nother than statements of historical fact are forward-looking statements.\nForward-looking statements are based on management's current assumptions and\nexpectations of future events and trends, which affect or may affect the\nCompany's business, strategy, operations or financial performance, and actual\nresults and other events may differ materially from those expressed or implied\nin such statements due to numerous risks and uncertainties. Forward-looking\nstatements are inherently subject to risks and uncertainties, some of which\ncannot be predicted or quantified. There are a number of important factors\nthat could cause actual results, developments, business decisions or other\nevents to differ materially from those contemplated by the forward-looking\nstatements in this press release. These factors include, among other things,\nour expectation that we will incur net losses for the foreseeable future; our\nability to become profitable; our ability to raise additional capital to\ncontinue our product development; our ability to accurately predict our future\noperating results; our ability to advance our current or future product\ncandidates through clinical trials, obtain marketing approval and ultimately\ncommercialize any product candidates we develop; the ability to obtain and\nmaintain regulatory approval of our product candidates; delays in completing\nthe development and commercialization of our current and future product\ncandidates; developing and commercializing additional products, including\ndiagnostic testing devices; our ability to compete in the marketplace;\ncompliance with applicable laws, regulations and tariffs, and factors\ndescribed in the Risk Factors section of our public filings with the\nSecurities and Exchange Commission (SEC). Because forward-looking statements\nare inherently subject to risks and uncertainties, you should not rely on\nthese forward-looking statements as predictions of future events. These\nforward-looking statements speak only as of the date of this press release\nand, except to the extent required by applicable law, the Company undertakes\nno obligation to update or revise these statements, whether as a result of any\nnew information, future events and developments or otherwise.\n\nContact Information\nInvestor Relations\nir@ainos.com\n\nSOURCE: Ainos, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/zacks-scr-discusses-ainos-expansion-of-smell-ai-into-healthcare-i-1172938)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-06-03T12:00:02.302874636Z","server_sent_at_ms":1780488002302},"received_at":"2026-06-03T12:00:02.452Z","source_url":"https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/zacks-scr-discusses-ainos-expansion-of-smell-ai-into-healthcare-i-1172938"},"analysis":{"id":"43039","press_release_id":"53609","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Zacks Small-Cap Research published an article discussing Ainos' expansion of its Smell AI technology into healthcare infrastructure.\n\nThe discussion centers on a study at National Taiwan University Hospital (NTUH) where Ainos' AI Nose is deployed in a live emergency department environment.\n\nThe article highlights the potential for Smell AI in environmental monitoring and healthcare, noting the generation of thousands of hours of monitoring data.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Third-party analyst commentary on existing NTUH study; no new material data."},"keyFigures":{},"quotedText":"The article reviews Ainos' initiative to deploy AI Nose in a live emergency department environment and explores the potential role of Smell AI in environmental monitoring, healthcare infrastructure, and artificial intelligence applications.","namedEntities":{"people":[],"products":["AI Nose","Smell ID","Smell Language Model","VELDONA"],"companies":[{"name":"Ainos, Inc.","ticker":"AIMD","relationship":"filer"},{"name":"Zacks Small-Cap Research","relationship":"analyst firm"},{"name":"National Taiwan University Hospital","relationship":"study partner"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a third-party research note discussion (Zacks SCR) regarding a previously announced study. It contains no new financial data, no new partnership agreement, and no new clinical results. It is essentially PR amplification of existing news."},"tickerRelevance":{"others":[],"primary":"AIMD"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"newData":false,"tickerTier":"small-cap","eventGravity":"analyst_commentary","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Zacks Small-Cap Research published an article discussing Ainos' expansion of its Smell AI technology into healthcare infrastructure.\n\nThe discussion centers on a study at National Taiwan University Hospital (NTUH) where Ainos' AI Nose is deployed in a live emergency department environment.\n\nThe article highlights the potential for Smell AI in environmental monitoring and healthcare, noting the generation of thousands of hours of monitoring data.","key_figures":{},"named_entities":{"people":[],"products":["AI Nose","Smell ID","Smell Language Model","VELDONA"],"companies":[{"name":"Ainos, Inc.","ticker":"AIMD","relationship":"filer"},{"name":"Zacks Small-Cap Research","relationship":"analyst firm"},{"name":"National Taiwan University Hospital","relationship":"study partner"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-04T05:56:29.271Z","global_importance":15,"audience_relevance":20,"importance_components":{"newData":false,"tickerTier":"small-cap","eventGravity":"analyst_commentary","issuerAuthored":true}},"durationMs":28227,"modelName":"george-droid-qwen-72b"}}